Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT-002 in NASH Phase Ib/IIa Trial
ChiCTR2300068706Phase 2Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BGT-002 in metabolic dysfunction-associated steatohepatitis (MASH) (8 arms), sponsored by The First Hospital of Jilin University. Primary endpoints: Safety and tolerability (symptoms and physical examination), Safety and tolerability (clinical laboratory examinations) and 2 more. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
BGT-002
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ChiCTR2300068706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068706.